`
`Pipeline
`
`A number of targeted anticancer compounds are now in clinical testing through our own product programs and
`those of our partners. Information on the relevant subtypes of each cancer can be found in the discussion of
`each compound.
`
`13 COMPOUNDS IN CLINICAL TESTING
`
`IMGN853
`Ovarian,
`endometrial
`
`IMGN529
`Non-Hodgkin
`lymphoma
`
`IMGN289
`Head, neck,
`lung, breast
`
`IMGN779
`AML
`
`Kadcyla®
`HER2+ mBC
`2nd-line
`
`HER2+ mBC
`1st line
`
`HER2+ BC
`
`Preclinical
`
`Preclinical
`
`Preclinical
`
`Preclinical
`
`Preclinical
`
`Pivotal/
`Phase III
`
`Preclinical
`
`Pivotal/
`Phase III
`
`Preclinical
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Phase I
`
`Phase I
`
`Phase I
`
`Phase I
`
`Marketed
`
`Phase I
`
`Phase I
`
`
`
`
`
`
`
`Phase II
`
`Phase II
`
`Phase II
`
`
`
`
`
`
`
`http://immunogen.com/pipeline/trastuzumab-emtansine/[1/19/2015 4:35:33 PM]
`
`IMMUNOGEN 2203, pg. 1
`Phigenix v. Immunogen
`IPR2014-00676
`
`
`
`ImmunoGen, Inc.: Pipeline
`
`others
`
`HER2+ gastric
`
`SAR3419
`DLBCL
`
`SAR650984*
`Multiple
`myeloma
`
`SAR566658
`Solid tumors
`
`SAR408701
`Solid tumors
`
`BT-062
`Multiple
`myeloma
`Breast,
`bladder
`
`BAY 94-
`9343
`Mesothelioma,
`ovarian
`
`AMG 595
`Glioblastoma
`
`AMG 172
`Kidney
`
`LOP628
`cKIT+ cancer
`
`Novartis 2
`Undisclosed
`
`
`
`
`
`
`
`
`
`Phase II
`
`
`
`Phase II
`
`Phase II
`
`Phase II
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Phase I
`
`Phase I
`
`Phase I
`
`Phase I
`
`Phase I
`
`Phase I
`
`Phase I
`
`Phase I
`
`Phase I
`
`Phase I
`
`Phase I
`
`Pivotal/
`Phase III
`
`Preclinical
`
`Pivotal/
`Phase III
`
`Preclinical
`
`Preclinical
`
`Preclinical
`
`Preclinical
`
`Preclinical
`
`Preclinical
`
`Preclinical
`
`Preclinical
`
`Preclinical
`
`Preclinical
`
`Preclinical
`
`http://immunogen.com/pipeline/trastuzumab-emtansine/[1/19/2015 4:35:33 PM]
`
`IMMUNOGEN 2203, pg. 2
`Phigenix v. Immunogen
`IPR2014-00676
`
`
`
`ImmunoGen, Inc.: Pipeline
`
`Novartis 3
`Undisclosed
`
`Novartis 4
`Undisclosed
`
`Novartis 5
`Undisclosed
`
`Novartis 6
`Undisclosed
`
`Lilly 1
`Undisclosed
`
`Lilly 2
`Undisclosed
`
`Lilly 3
`Undisclosed
`
`Preclinical
`
`Preclinical
`
`Preclinical
`
`Preclinical
`
`Preclinical
`
`Preclinical
`
`Preclinical
`
`Earlier stage compounds in development by ImmunoGen and our partners.
`
`ImmunoGen
`Novartis
`
`
`
`
`
`
`Lilly
`
`
`
`
`
`Roche
`
`
`
`
`
`Sanofi
`
`
`
`
`
`Biotest
`
`
`
`
`
`Bayer
`
`
`
`
`
`Amgen
`
`
`
`Kadcyla® is a registered trademark of Genentech, a member of the Roche Group.
`
`* Therapeutic antibody
`
`mBC: metastatic breast cancer
`BC: breast cancer
`DLBCL: diffuse large B-cell lymphoma
`
`Based on information on clinicaltrials.gov or other public disclosures.
`
`Last updated: January 15, 2015
`
`http://immunogen.com/pipeline/trastuzumab-emtansine/[1/19/2015 4:35:33 PM]
`
`IMMUNOGEN 2203, pg. 3
`Phigenix v. Immunogen
`IPR2014-00676
`
`
`
`ImmunoGen, Inc.: Pipeline
`
`© 2015 ImmunoGen, Inc.
`
` Sitemap | Privacy Policy | Usage Policy
`
`http://immunogen.com/pipeline/trastuzumab-emtansine/[1/19/2015 4:35:33 PM]
`
`IMMUNOGEN 2203, pg. 4
`Phigenix v. Immunogen
`IPR2014-00676
`
`